Enovis Shares Surge 11% After Medicare Reversal

Enovis Shares Surge 11% After Medicare Reversal

Enovis Corp shares rose approximately 11% on Monday after the Centers for Medicare & Medicaid Services (CMS) announced it would reverse previously announced reimbursement cuts for the company's non‑invasive bone growth stimulators. The CMS decision restores the earlier reimbursement rates that had been slated for reduction, thereby preserving anticipated revenue from the bone growth stimulator product line. The market reaction reflects investor optimism that the reversal will sustain the company's cash flow and profitability from its medical device offerings. No further details on the magnitude of the reimbursement cuts or the duration of the reversal were provided.